
Wisconsin's 'Golden Handcuffs': State Methadone Rules Keep Patients Shackled to Daily Clinic Visits
Bob wakes up at 4:30 a.m. and begins the 40-minute drive to his methadone clinic. Years ago, he left that early to make it to work on time. Now retired, he simply likes to beat the crowd.
The 70-year-old Stevens Point resident has maintained this routine for more than half his life. He credits methadone treatment for his long career and ability to raise two daughters. Now he sits in a recliner holding a sheet of paper with a list of old friends, several names marked with "OD" next to loved ones killed by drugs.
"Methadone is like having a pair of golden handcuffs," he says.
More than 10,000 Wisconsinites relied on methadone treatment in 2024 to recover from opioid use disorder. The medication reduces drug cravings, prevents withdrawal, and can provide stability without producing a mind-altering high. Research consistently shows it is highly effective at reducing illicit opioid use and overdoses.
Yet Wisconsin's regulatory framework makes accessing this life-saving treatment considerably more difficult than in neighboring states. While the federal government sets minimum standards for clinics aimed at preventing misuse, Wisconsin adds more than a dozen additional restrictive requirements, according to the Pew Charitable Trusts. For patients, these state laws can mean waiting longer to enroll in treatment, making daily drives to the clinic even on weekends and holidays, and taking longer to reach an effective dose.
The Daily Grind
Unlike other medications for opioid use disorder, methadone cannot be picked up from a pharmacy. Only 31 locations across Wisconsin are approved to provide medication-assisted treatments including methadone, according to the state health department. At the state's northernmost clinic in Wausau, patients traveled an average of 31 miles one way in 2024.
Bob tries not to use the bathroom before starting his morning drive. He knows clinic staff will likely send him into the bathroom with a cup as soon as he arrives. It has been two decades since he used drugs or alcohol, but he takes the drug test all the same.
Next, he walks up to a clinic window, where someone hands him 13 plastic bottles of cherry-red liquid. Bob locks the medications inside a box he brought from home. A staff member watches as he swallows another dose. He will repeat this entire process in 13 days.
Wisconsin vs. Federal Standards
Methadone can be fatal if misused, so the federal government has historically limited the number of take-home doses patients receive. Early in the pandemic, federal regulators allowed states to relax these rules to limit crowding at clinics. Studies later showed higher patient satisfaction and feelings of being respected without a significant increase in misuse.
In making these pandemic exceptions permanent in 2024, federal regulators wrote that previous standards "can pose disruption to employment, education and other daily activities for patients, and several of the criteria reflect outdated biases that promote stigma and discourage people from engaging in care."
But Wisconsin's take-home regulations remain stricter than the federal minimums from before the pandemic. The federal standard allows stable patients to take home 28 doses at a time. Wisconsin allows only 13.
Wisconsin patients must visit their clinic seven days a week until they complete a month in treatment and meet other criteria not required by the federal government. It takes a year in Wisconsin to qualify for the number of take-home doses providers in other states can offer patients after two weeks.
State code also caps initial methadone doses at 30 milligrams, an outdated limit in the fentanyl era. The average dose at most Wisconsin clinics in 2024 was above 100 milligrams. Updated federal limits allow providers to start patients at 50 milligrams or higher based on clinical judgment. A higher starting dose can help patients avoid withdrawal and reach a stable dose sooner.
Random Callbacks and Disrupted Lives
State rules require clinics to regularly "call back" patients who have more than two take-home doses. Between visits, providers often call and tell patients to arrive at the clinic within 24 hours with all their methadone bottles. If they do not comply, they must return to daily clinic visits.
Federal rules do not require callbacks. In a 2024 report, federal regulators said providers should "consider the disruptive nature of random callbacks."
"It is hard to make plans knowing you might have to change them any moment," Bob says. "I want to be normal again."
A Tale of Two States
Timothy overdosed three times before starting treatment. After nine months in Marathon County jail, he relapsed unaware of his lowered tolerance and the strength of the 2022 drug supply. Within a couple of months, he started methadone.
"Some people do not get out of that. A lot of people do not," Timothy said. "I am grateful."
Despite attending regular counseling and dosing in-person daily for four years, Timothy still does not qualify for a single take-home dose in Wisconsin. That is because he started using cannabis while undergoing chemotherapy around the time he began methadone treatment. Now in remission, he is working with his counselor to stop using cannabis, but it still prevents him from receiving take-home doses under state rules.
In other states, marijuana use does not bar patients from receiving take-homes.
Last month, Timothy received two take-home methadone bottles while visiting his daughter in Florida. Before leaving Wisconsin, he worked with staff at his clinic to set up a week's worth of visits with a Florida provider. He was surprised when the new clinic told him he would receive take-home doses over the weekend.
When at home in Wisconsin, Timothy does not mind the daily clinic visits. But when he is with his daughter, they remind him of his past mistakes. For two days he mixed his medication with apple juice and celebrated his 45th birthday with his family without stopping at the clinic.
He said it was the best time of his life.
The Path Forward
Wisconsin is an outlier whose policies are overdue for an update, said Sharel Rogers, CEO of Addiction Medical Solutions and Vin Baker Recovery. She also serves as president of the Wisconsin Association of Treatment for Opioid Dependence.
Rogers was among several providers who backed a bill last month to update state rules. The measure was introduced right before the legislative session ended and was not expected to pass, but supporters hoped it would push regulators to act.
The Wisconsin Department of Health Services is reviewing the state's opioid treatment regulations through what a spokesperson called an "intentionally thorough" rulemaking process started last year to bring state regulations "closer in alignment with current federal regulations." The agency is still drafting proposed changes, which would be subject to public hearings and lawmaker approval.
Opioid overdose deaths dropped by more than 42% in Wisconsin between 2023 and 2024, according to the state health department. Still, opioids killed 815 people in Wisconsin in 2024, compared with fewer than 300 deaths two decades earlier.
"The regulations in Wisconsin bind us to creating a one size fits all plan, and that is just not how humans work," said Dr. Hillary Tamar, who oversees Wisconsin treatment providers as a medical director for Community Medical Services.
Other states have already moved forward. Minnesota, Michigan, Illinois, and Iowa have all adopted newer standards that expand access without compromising patient safety. For patients like Bob and Timothy, such changes cannot come soon enough.
Editorial Board
LADC, LCPC, CASAC
The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.
Related Articles

One in Five Pharmacies Block Access to Buprenorphine, Study Finds
New research reveals 20% of U.S. pharmacies refuse to dispense buprenorphine, creating critical barriers to opioid addiction treatment despite federal expansion efforts.

Medicaid Expansion Drives 21% Surge in Buprenorphine Access Across Eight States
New JAMA study shows Medicaid expansion significantly increased access to buprenorphine for opioid use disorder, with Oklahoma seeing 43% drop in overdose deaths.

South Dakota Counties Slow to Spend Opioid Settlement Funds as Crisis Continues
Local governments in South Dakota have spent less than half of $9.6 million in opioid settlement funds, raising questions about accountability and effective crisis response.